lucius卢修斯埃拉菲布拉诺 Elafibranor胆汁性胆管炎

埃拉菲布拉诺

美国FDA批准上市产品,疗效确切
卢修斯制药(老挝)有限公司出品

Elafibranor

老挝国家食药监局批准上市
老挝国家药检所检测认证

胆汁性胆管炎

Composition
Each film-coated tabletcontains
Elafibranor ...

LUCIUS

-.... 80mg

LueiElatib is a peroxisome pronterator-

PHARMACEUTICALS

activated receotor (PPAR) agonist indicated fo
the treatment of primary biliary cholangitis
DC) in combination with ursodeoxycholic
acid(UDC Alin adalts who have an madequa

LuciElafib

response to UDCA, or as monolherapy in
patients unable to tolerate UDCA
Dosage ano Usci

80 mg

FDA批准

The recommendod d
mended dosage is 80 mg orally once
dasly with or without food
Storage: in a dry place and store at 20°C to 25°C.
Warning:
Keep medicine out of reach of Children. Do no

Elafibranor Tablets

administer LuciElafib during Pregnancy and
PLEASE SEE PACKAGE INSERT
Manufactured and Marketed by:

Rx Only

LUCIUIS

权威认证

Thongmang village, Xaythany district.
Vientiane Capital. Laos
www.lucrus.la
Warning: Tohe sold by retail on prescrintio
of registered pliysicians onlv, and as directed

30 Tablets

口碑质量

适应症:

埃拉菲布拉诺是一种过氧化物酶体增生激活受体(PPAR)激动剂,
与熊去氧胆酸(UDCA)联合使用,适用于对UDCA反应不足的成人
原发性胆汁性胆管炎(PBC)的治疗,或作为单药用于无法耐受
UDCA的患者。

推荐剂量:

1、治疗前,评估肌肉疼痛或肌病,和/或确认有生育能力的女性没有
怀孕。
2、推荐剂量为每日口服一次,每次80mg,可随餐服用亦可单独服
用。